Prevzaté: Rituximab therapy in adult patients with relapsed or refractory ITP Posted on 30.10.2009 17:41
Topic: Trombocytopenia
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results
Marta Medeot1, Francesco Zaja1, Nicola Vianelli2, Marta Battista1, Michele Baccarani2, Francesca Patriarca1, Franca Soldano3, Miriam Isola3, Stefano De Luca1, Renato Fanin1
1Clinica Ematologica, DIRM, University of Udine, Udine, Italy; 2Istituto di Ematologia ed Oncologia Medica L. e A. Seragnoli, Bologna, Italy; 3Istituto di Statistica, DIRM, University of Udine, Udine, Italy
European Journal of Haematology 2008 81 (165-169)
Correspondence Francesco Zaja, MD, Clinica Ematologica, University of Udine, P.zza S. Maria della Misericordia, 33100 Udine, Italy.
Tel: +39 432 559604; Fax: +39 432 559661; e-mail: zaja.francesco@aoud.sanita.fvg.it
<>
Abstract
Objective: To evaluate the long-term activity and toxicity profile of rituximab in adult patients with idiopathic immune thrombocytopenic purpura (ITP). Patients and methods: Twenty-six patients with active and symptomatic ITP relapsed or refractory received weekly infusions of rituximab 375 mg⁄m2 for 4 wk. Median time from diagnosis to rituximab was 34.5 months. The following parameters of efficacy and toxicity were considered: complete response (CR) and partial response (PR), relapse rate, relapse-free survival (RFS), therapy - free survival (TFS), short- and long-term toxicity.
Results: CR and PR were 14 ⁄ 26 (54%) and 4 ⁄ 26 (15%), respectively. Median time of observation was 56.5 months (range 39-77). Nine of the 18 responding patients relapsed after a median of 21 months (range 8-66); 9 ⁄ 26 patients (35%) maintained the response, with a median follow-up of 57 months (range 39-69), and 11 ⁄ 26 (42%) did not necessitate further therapy; estimated 5 yr RFS and TFS were 61% and 72%, respectively. Younger age and shorter interval from diagnosis to rituximab appeared indicators of better outcome. Rituximab administration was associated with two episodes of short-term toxicity, with one case of serum sickness syndrome; no infectious or other significant long-term complications were documented.
Conclusion: Rituximab therapy may achieve long-lasting remission in nearly one-third of patients with relapsed or refractory ITP, with a good safety profile.
Key words immune thrombocytopenic purpura; rituximab; long-term activity
pozri článok
|
|
| |
Ešte nemáte konto? Môžete si ho vytvoriť. Registrovaný užívateľ má niektoré výhody, napr. manažér tém, nastavenie komentárov a posielanie komentárov s vlastným menom. |
|
Priemerné skóre: 1 hlasov: 1
|
|
|